ArticleBMC medical genomics2026
MicroRNA-205-5p: a candidate biomarker and mechanistic mediator in polycystic ovary syndrome.
Article in BMC medical genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe objective of this study was to investigate the impact of microRNA-205-5p (miR-205-5p) on clinical outcomes in patients with polycystic ovary syndrome (PCOS).
methodsEighty PCOS patients and sixty-five healthy individuals were enrolled in this retrospective study. Serum levels of miR-205-5p were measured using quantitative reverse transcription polymerase chain reaction (qRT-PCR). The diagnostic efficacy was assessed using receiver operating characteristic (ROC) curves. Logistic regression analysis was conducted to identify the risk factors for insulin resistance (IR) in PCOS patients. Additionally, bioinformatics analysis was performed for the functional enrichment of miR-205-5p targets.
resultsSerum levels of miR-205-5p were significantly elevated in PCOS patients, particularly in those with IR (P < 0.001). A high diagnostic accuracy of serum miR-205-5p was displayed for distinguishing PCOS patients from healthy controls (AUC = 0.955) and for distinguishing IR from non-IR among PCOS patients (AUC = 0.852). Moreover, miR-205-5p exhibited a positive correlation with the HOMA-IR value (r = 0.6930, P < 0.001). Abnormal levels of miR-205-5p were significantly associated with BMI, FINS, FBG and HOMA-IR in PCOS patients with IR (all P < 0.001). Furthermore, miR-205-5p was identified as an independent risk factor for IR in PCOS patients, demonstrating a substantial effect size (P = 0.014; OR = 3.849;95%CI = 1.313-11.280), indicating that elevated levels of miR-205-5p were associated with a 3.849-fold increased risk of IR among this population. Bioinformatic analysis and luciferase reporter assays identified SMAD4 as a potential target of miR-205-5p.
conclusionsMiR-205-5p expression was significantly elevated in PCOS patients with IR, suggesting its potential as a non-invasive biomarker for the early detection of IR in this cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.